Vertex Pharmaceuticals Incorporated is a leading biotechnology firm primarily focused on the discovery, advancement, and marketing of innovative treatments, particularly for cystic fibrosis (CF). The company offers a range of approved medications for CF patients, including SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO, which target specific mutations within the cystic fibrosis transmembrane conductance regulator gene. Additionally, they provide TRIKAFTA for individuals with CF aged six years and older who possess at least one F508del mutation. Beyond its established CF therapies, Vertex maintains a…
HERE ARE THE COMPANIES REPORTING EARNINGS AFTER THE BELL TODAY Including Apple and Palantir Apple $AAPL • EPS: $1.98 est • Revenue: $112.95B est Palantir $PLTR • EPS: $0.40 est • Revenue: $2.17B est Vertex Pharmaceuticals $VRTX • EPS: $4.92 est • Revenue: $3.40B est…
HERE'S WHAT THE ?? STOCK MARKET LOOKS LIKE SO FAR TODAY ??? Up • Regeneron $REGN +11.5% • T-Mobile $TMUS +6.6% • Accenture $ACN +4.5% • Mondelez $MDLZ +4.0% • Intercontinental Exchange $ICE +3.8% • Republic Services $RSG +3.8% • Vertex Pharmaceuticals $VRTX +3.8% •…
Red all around as the sell-off accelerates. But amazingly enough, there are some stocks out there hitting new all-time highs. $XOM $CVX $SHEL $COP $LNG $PR $GILD $JNJ $ABBV $LLY $VRTX $AMGN $V $MA $ED $CB $CAH $PM $BRK.B to name a few.
Earnings galore too. $AAPL $PLTR $VRTX $MAR $ON $FOXA $ROKU $AMD $AMGN $SHOP $PFE $ETN $BKNG $RACE $APO $KDP $XYZ $YUM $SYY $ARM $QCOM $NVO $MCD $UBER $CVS $MCK $DDOG $APP $ALL $MET $AFL $CRCL Barron's/Dow Jones owner $NWSA $COP $SONY $MNST $ABNB $LITE $MRNA $HUM $VST + many more
$VRTX ... The drugs are working....stocks that is.... I hope it does not wear off soon... Vertex reports earnings on Monday https://t.co/2PZ3UDKQtz
HERE'S WHAT THE ?? STOCK MARKET LOOKED LIKE TODAY Up: UnitedHealth $UNH +4.8% Merck $MRK +3.8% Gilead Sciences $GILD +3.8% Eli Lilly $LLY +3.8% Lockheed Martin $LMT +3.6% Walmart $WMT +3.5% AbbVie $ABBV +3.4% Vertex Pharmaceuticals $VRTX +3.3% Down: Dell $DELL -11.4% Flex $FLEX…
29 analysts rate VRTX Buy on consensus.
Consensus price target: $571.39 (+7.66% upside from $530.76)
| Insider | Date | Transaction | Shares | Value |
|---|---|---|---|---|
| Bozic Carmen EVP and CMO | Jun 15, 2026 | Sale | 4,062 | $1.83M |
| Bozic Carmen EVP and CMO | May 12, 2026 | Sale | 6,988 | $3.14M |
| Liu Joy EVP and Chief Legal Officer | Apr 1, 2026 | Sale | 978 | $439.29K |
| McKechnie Duncan EVP, Chief Commercial Officer | Mar 11, 2026 | Sale | 2,633 | $1.31M |
| McKechnie Duncan EVP, Chief Commercial Officer | Mar 4, 2026 | Sale | 2,437 | $1.16M |
| Fiscal year | Revenue | Revenue YoY | Net income |
|---|---|---|---|
| 2025 | $12.07B | +9.57% | $3.95B |
| 2024 | $11.02B | +11.66% | $-535.6M |
| 2023 | $9.87B | +10.51% | $3.62B |
Stock data for VRTX: Summary · AI Insight · Feed · News · Financials · Transcript · SEC Filings · Insider · Politics